IMARC Group has recently released a report titled “Opioid-Induced Constipation Market: Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast (2023-2033)” that presents a comprehensive assessment of the opioid-induced constipation market report, latest trends, and growth forecast. The report provides an extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth analysis of the disease landscape, market scenario, and growth trends. Furthermore, the report offers an analysis of competitors, regional markets, and recent advancements in the global market. It also sheds light on crucial segments and market drivers, along with challenges faced by industry players. This report is a valuable resource for stakeholders who want to gain valuable insights into the opioid-induced constipation market.
Opioid-induced constipation refers to a type of chronic constipation mainly caused by opioids, which activate enteric receptors and increase tonic non-propulsive contractions in the small and large intestines. This can slow down the movement of the stool through the digestive system, resulting in difficulty passing stool and infrequent bowel movements. The common symptoms associated with the opioid-induced constipation ailment include bloating, distention, abdominal tenderness, alternating episodes of constipation and diarrhea or bulging in the abdomen, dry and hard stools, nausea, vomiting, fatigue, weight loss, difficulty defecating, etc. The diagnosis is typically based on the evaluation of the patient’s symptoms, along with a physical and rectal examination to visualize stool impaction and abdominal distension.
Request a Free Sample Report: https://www.imarcgroup.com/opioid-induced-constipation-market/requestsample
The increasing usage of opioid medications for acute pain, like after surgery or injury, and chronic pain, including that associated with cancer or certain other medical conditions, is primarily augmenting the opioid-induced constipation market. Additionally, the rising adoption of effective drugs, such as mu-opioid receptor antagonists and chloride channel type-2 activators, which aid in improving intestinal relaxation and stool movements to provide symptom relief, is further propelling the market growth.
Moreover, the elevating application of various diagnostic tools, including Patient Assessment of Constipation Symptoms (PAC-SYM) and PAC-Quality of Life (PAC-QOL), to measure abdominal and rectal symptoms is creating a positive outlook for the market. Besides this, several leading players are making heavy investments in R&D activities to introduce injectable opioid antagonists to treat advanced illnesses among patients, which is also stimulating the market growth. Furthermore, the emerging popularity of the hybrid approach, which includes pharmacological therapy and lifestyle modifications such as increasing dietary fiber, maintaining physical wellness, focusing on fluid intake, etc., for treating the ailment, is projected to fuel the opioid-induced constipation market in the coming years.
Report Period:
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Countries Included:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the opioid-induced constipation market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the opioid-induced constipation market
- Reimbursement scenario in the market
- In-market and pipeline drugs
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Regulatory Status
Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/opioid-induced-constipation-market
Key Questions Answered in this Report:
- How has the opioid-induced constipation market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
- What was the country-wise size of the opioid-induced constipation market across the seven major markets in 2022 and what will it look like in 2033?
- What is the growth rate of the opioid-induced constipation market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Browse the Latest Research Report:
Hepatitis B Market Report 2023-2033
Lymphedema Market Report 2023-2033
Intratumoral Cancer Therapies Market Report 2023-2033
Hyperuricemia Market Report 2023-2033
About Us: –
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
Comments
0 comment